|
Cannabis Campaigners' Guide News Database result:
|
|
UK: GW Pharmaceuticals says cannabis-based drug trials show positive results
Ananova Monday 10 Sep 2001 GW Pharmaceuticals PLC said preliminary safety and efficacy data from its Phase One and Two clinical trials of its cannabis-based medicines showed very positive results. Of the 53 multiple sclerosis and spinal cord injury patients in the studies, 41 derived clinically significant benefit, it said. The data also confirms that the company's medicines have an excellent safety profile, it added. It said the data show that active treatments provide superior benefit to placebo in key outcomes, including pain, overall symptom relief and sleep duration. The data show clear trends which support the clinical improvements experienced by patients whose conditions have been considered intractable in the face of standard therapy, it said. In some cases, the improvements have been sufficient to transform lives, it added. It said adverse events of the studies have been predictable and generally well-tolerated, adding most patients are able to separate the thresholds for symptom relief and intoxication by careful dose adjustment. GW also said the Medicines Control Agency (MCA) has approved the extended use of the company's cannabis-based medicines from 12 months to 24 months treatment. Executive chairman Geoffrey Guy said: "We remain confident of being able to present data on quality, safety, and efficacy to the UK regulatory authorities in 2003, and - subject to approval - bring the first cannabis-based prescription medicine to market in early 2004."
After you have finished reading this article you can click here to go back.
|
This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!